To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists
To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists is a medical device with 1 clinical trials. Currently 1 active trials ongoing.
Registry-listed formulations
This catalogue entry has no confirmed scientific concept.
Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.
1 source entries across 1 studies. This list may not include all unresolved or historical entries.
- To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonistsRegistry intervention
Linked study entry; product equivalence not established
View study and source
Success Metrics
Phase Distribution
No phase data available
Trial Status & Enrollment
0.0%
0 of 0 finished
0.0%
0 ended early
1
trials recruiting
1
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Status
Recent Activity
Clinical Trials (1)
All 1 trials loaded
Drug Details
- Intervention Type
- Device
- Total Trials
- 1